位置:首页 > 蛋白库 > PAK3_MOUSE
PAK3_MOUSE
ID   PAK3_MOUSE              Reviewed;         559 AA.
AC   Q61036; O88645; Q8K1R5; Q8K1R6;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   10-MAY-2004, sequence version 2.
DT   03-AUG-2022, entry version 203.
DE   RecName: Full=Serine/threonine-protein kinase PAK 3;
DE            EC=2.7.11.1;
DE   AltName: Full=Beta-PAK;
DE   AltName: Full=CDC42/RAC effector kinase PAK-B;
DE   AltName: Full=p21-activated kinase 3;
DE            Short=PAK-3;
GN   Name=Pak3; Synonyms=Pak-3, Pakb, Stk4;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Fibroblast;
RX   PubMed=7559398; DOI=10.1074/jbc.270.39.22731;
RA   Bagrodia S., Taylor S.J., Creasy C.L., Chernoff J., Cerione R.A.;
RT   "Identification of a mouse p21Cdc42/Rac activated kinase.";
RL   J. Biol. Chem. 270:22731-22737(1995).
RN   [2]
RP   ERRATUM OF PUBMED:7559398.
RA   Bagrodia S., Taylor S.J., Creasy C.L., Chernoff J., Cerione R.A.;
RL   J. Biol. Chem. 271:1250-1250(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=10352232; DOI=10.1016/s0378-1119(99)00110-9;
RA   Burbelo P.D., Kozak C.A., Finegold A.A., Hall A., Pirone D.M.;
RT   "Cloning, central nervous system expression and chromosomal mapping of the
RT   mouse PAK-1 and PAK-3 genes.";
RL   Gene 232:209-215(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Brain;
RX   PubMed=12464619; DOI=10.1074/jbc.m207251200;
RA   Rousseau V., Goupille O., Morin N., Barnier J.V.;
RT   "A new constitutively active brain Pak3 isoform displays modified
RT   specificities towards Rac and Cdc42 GTPases.";
RL   J. Biol. Chem. 278:3912-3920(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   STRAIN=C57BL/6J; TISSUE=Medulla oblongata;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., Davis M.J.,
RA   Wilming L.G., Aidinis V., Allen J.E., Ambesi-Impiombato A., Apweiler R.,
RA   Aturaliya R.N., Bailey T.L., Bansal M., Baxter L., Beisel K.W., Bersano T.,
RA   Bono H., Chalk A.M., Chiu K.P., Choudhary V., Christoffels A.,
RA   Clutterbuck D.R., Crowe M.L., Dalla E., Dalrymple B.P., de Bono B.,
RA   Della Gatta G., di Bernardo D., Down T., Engstrom P., Fagiolini M.,
RA   Faulkner G., Fletcher C.F., Fukushima T., Furuno M., Futaki S.,
RA   Gariboldi M., Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N., Hill D.,
RA   Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T., Jakt M.,
RA   Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H., Kitano H.,
RA   Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K., Kurochkin I.V.,
RA   Lareau L.F., Lazarevic D., Lipovich L., Liu J., Liuni S., McWilliam S.,
RA   Madan Babu M., Madera M., Marchionni L., Matsuda H., Matsuzawa S., Miki H.,
RA   Mignone F., Miyake S., Morris K., Mottagui-Tabar S., Mulder N., Nakano N.,
RA   Nakauchi H., Ng P., Nilsson R., Nishiguchi S., Nishikawa S., Nori F.,
RA   Ohara O., Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G.,
RA   Pesole G., Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z.,
RA   Ringwald M., Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B., Sperling S.,
RA   Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K., Tammoja K.,
RA   Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A., Ueda H.R.,
RA   van Nimwegen E., Verardo R., Wei C.L., Yagi K., Yamanishi H.,
RA   Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C., Grimmond S.M.,
RA   Teasdale R.D., Liu E.T., Brusic V., Quackenbush J., Wahlestedt C.,
RA   Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y., Fukuda S.,
RA   Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T., Iida J., Imamura K.,
RA   Itoh M., Kato T., Kawaji H., Kawagashira N., Kawashima T., Kojima M.,
RA   Kondo S., Konno H., Nakano K., Ninomiya N., Nishio T., Okada M., Plessy C.,
RA   Shibata K., Shiraki T., Suzuki S., Tagami M., Waki K., Watahiki A.,
RA   Okamura-Oho Y., Suzuki H., Kawai J., Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   STRAIN=C3H/He; TISSUE=Mesenchymal stem cell;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION IN PHOSPHORYLATION OF TNNI3.
RX   PubMed=12242269; DOI=10.1161/01.res.0000035246.27856.53;
RA   Buscemi N., Foster D.B., Neverova I., Van Eyk J.E.;
RT   "p21-activated kinase increases the calcium sensitivity of rat triton-
RT   skinned cardiac muscle fiber bundles via a mechanism potentially involving
RT   novel phosphorylation of troponin I.";
RL   Circ. Res. 91:509-516(2002).
RN   [8]
RP   FUNCTION, AND MUTAGENESIS OF LYS-312.
RX   PubMed=15574732; DOI=10.1523/jneurosci.2931-04.2004;
RA   Boda B., Alberi S., Nikonenko I., Node-Langlois R., Jourdain P.,
RA   Moosmayer M., Parisi-Jourdain L., Muller D.;
RT   "The mental retardation protein PAK3 contributes to synapse formation and
RT   plasticity in hippocampus.";
RL   J. Neurosci. 24:10816-10825(2004).
RN   [9]
RP   FUNCTION, AND MUTAGENESIS OF HIS-78; HIS-81; LYS-312 AND THR-436.
RX   PubMed=15800193; DOI=10.1523/jneurosci.3553-04.2005;
RA   Zhang H., Webb D.J., Asmussen H., Niu S., Horwitz A.F.;
RT   "A GIT1/PIX/Rac/PAK signaling module regulates spine morphogenesis and
RT   synapse formation through MLC.";
RL   J. Neurosci. 25:3379-3388(2005).
RN   [10]
RP   DISRUPTION PHENOTYPE.
RX   PubMed=16014725; DOI=10.1523/jneurosci.0028-05.2005;
RA   Meng J., Meng Y., Hanna A., Janus C., Jia Z.;
RT   "Abnormal long-lasting synaptic plasticity and cognition in mice lacking
RT   the mental retardation gene Pak3.";
RL   J. Neurosci. 25:6641-6650(2005).
RN   [11]
RP   FUNCTION, AND MUTAGENESIS OF ARG-67.
RX   PubMed=17537723; DOI=10.1074/jbc.m703298200;
RA   Kreis P., Thevenot E., Rousseau V., Boda B., Muller D., Barnier J.V.;
RT   "The p21-activated kinase 3 implicated in mental retardation regulates
RT   spine morphogenesis through a Cdc42-dependent pathway.";
RL   J. Biol. Chem. 282:21497-21506(2007).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-186, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and expression.";
RL   Cell 143:1174-1189(2010).
RN   [13]
RP   FUNCTION IN PHOSPHORYLATION OF TNNI3.
RX   PubMed=20540949; DOI=10.1016/j.jmb.2010.06.007;
RA   Ouyang Y., Mamidi R., Jayasundar J.J., Chandra M., Dong W.J.;
RT   "Structural and kinetic effects of PAK3 phosphorylation mimic of
RT   cTnI(S151E) on the cTnC-cTnI interaction in the cardiac thin filament.";
RL   J. Mol. Biol. 400:1036-1045(2010).
RN   [14]
RP   DISRUPTION PHENOTYPE.
RX   PubMed=21115725; DOI=10.1128/mcb.00969-10;
RA   Huang W., Zhou Z., Asrar S., Henkelman M., Xie W., Jia Z.;
RT   "p21-Activated kinases 1 and 3 control brain size through coordinating
RT   neuronal complexity and synaptic properties.";
RL   Mol. Cell. Biol. 31:388-403(2011).
RN   [15]
RP   FUNCTION.
RX   PubMed=25851601; DOI=10.1091/mbc.e14-08-1310;
RA   Jaudon F., Raynaud F., Wehrle R., Bellanger J.M., Doulazmi M., Vodjdani G.,
RA   Gasman S., Fagni L., Dusart I., Debant A., Schmidt S.;
RT   "The RhoGEF DOCK10 is essential for dendritic spine morphogenesis.";
RL   Mol. Biol. Cell 26:2112-2127(2015).
RN   [16]
RP   STRUCTURE BY NMR OF 65-92 AND 108-123 IN COMPLEX WITH CDC42.
RX   PubMed=10747784; DOI=10.1021/bi992646d;
RA   Gizachew D., Guo W., Chohan K.K., Sutcliffe M.J., Oswald R.E.;
RT   "Structure of the complex of Cdc42Hs with a peptide derived from P-21
RT   activated kinase.";
RL   Biochemistry 39:3963-3971(2000).
CC   -!- FUNCTION: Serine/threonine protein kinase that plays a role in a
CC       variety of different signaling pathways including cytoskeleton
CC       regulation, cell migration, or cell cycle regulation. Plays a role in
CC       dendrite spine morphogenesis as well as synapse formation and
CC       plasticity (PubMed:25851601). Acts as downstream effector of the small
CC       GTPases CDC42 and RAC1. Activation by the binding of active CDC42 and
CC       RAC1 results in a conformational change and a subsequent
CC       autophosphorylation on several serine and/or threonine residues.
CC       Phosphorylates MAPK4 and MAPK6 and activates the downstream target
CC       MAPKAPK5, a regulator of F-actin polymerization and cell migration.
CC       Additionally, phosphorylates TNNI3/troponin I to modulate calcium
CC       sensitivity and relaxation kinetics of thin myofilaments. May also be
CC       involved in early neuronal development. In hippocampal neurons,
CC       necessary for the formation of dendritic spines and excitatory
CC       synapses; this function is dependent on kinase activity and may be
CC       exerted by the regulation of actomyosin contractility through the
CC       phosphorylation of myosin II regulatory light chain (MLC)
CC       (PubMed:15800193). {ECO:0000269|PubMed:12242269,
CC       ECO:0000269|PubMed:15574732, ECO:0000269|PubMed:15800193,
CC       ECO:0000269|PubMed:17537723, ECO:0000269|PubMed:20540949,
CC       ECO:0000269|PubMed:25851601}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- ACTIVITY REGULATION: Activated by binding small G proteins. Binding of
CC       GTP-bound CDC42 or RAC1 to the autoregulatory region releases monomers
CC       from the autoinhibited dimer, enables phosphorylation of Thr-436 and
CC       allows the kinase domain to adopt an active structure (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBUNIT: Interacts tightly with GTP-bound but not GDP-bound CDC42/p21
CC       and RAC1. Shows highly specific binding to the SH3 domains of
CC       phospholipase C-gamma and of adapter protein NCK. Interacts with the C-
CC       terminal of APP. Interacts with ARHGEF6 and ARHGEF7 (By similarity).
CC       Interacts with GIT1 and GIT2 (By similarity). {ECO:0000250,
CC       ECO:0000250|UniProtKB:O75914}.
CC   -!- INTERACTION:
CC       Q61036; P60953: CDC42; Xeno; NbExp=3; IntAct=EBI-457317, EBI-81752;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q61036-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q61036-2; Sequence=VSP_010243;
CC   -!- PTM: Autophosphorylated when activated by CDC42/p21.
CC   -!- PTM: Neddylated. {ECO:0000250}.
CC   -!- DISRUPTION PHENOTYPE: Mice show significant abnormalities in synaptic
CC       plasticity as well as deficiencies in learning and memory. Pak1 and
CC       Pak3 double knockout mice display reduced brains characterized by
CC       simplified neuronal dendrites/axons and reduced synapse density.
CC       {ECO:0000269|PubMed:16014725, ECO:0000269|PubMed:21115725}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. STE20 subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U39738; AAC52354.1; -; mRNA.
DR   EMBL; AF082297; AAC31969.1; -; mRNA.
DR   EMBL; AJ496262; CAD42790.1; -; mRNA.
DR   EMBL; AJ496263; CAD42791.1; -; mRNA.
DR   EMBL; AK031853; BAC27580.1; -; mRNA.
DR   EMBL; BC053403; AAH53403.1; -; mRNA.
DR   CCDS; CCDS30454.1; -. [Q61036-2]
DR   CCDS; CCDS57779.1; -. [Q61036-1]
DR   PIR; I49376; I49376.
DR   RefSeq; NP_001181977.1; NM_001195048.1. [Q61036-1]
DR   RefSeq; NP_001181978.1; NM_001195049.1. [Q61036-2]
DR   RefSeq; NP_032804.2; NM_008778.3. [Q61036-2]
DR   RefSeq; XP_006528815.1; XM_006528752.3. [Q61036-1]
DR   RefSeq; XP_006528816.1; XM_006528753.3. [Q61036-2]
DR   RefSeq; XP_006528817.1; XM_006528754.3. [Q61036-2]
DR   RefSeq; XP_011246092.1; XM_011247790.2. [Q61036-2]
DR   RefSeq; XP_017173912.1; XM_017318423.1.
DR   PDB; 1EES; NMR; -; B=63-123.
DR   PDBsum; 1EES; -.
DR   AlphaFoldDB; Q61036; -.
DR   SMR; Q61036; -.
DR   BioGRID; 202021; 16.
DR   DIP; DIP-447N; -.
DR   IntAct; Q61036; 6.
DR   MINT; Q61036; -.
DR   STRING; 10090.ENSMUSP00000108485; -.
DR   iPTMnet; Q61036; -.
DR   PhosphoSitePlus; Q61036; -.
DR   EPD; Q61036; -.
DR   jPOST; Q61036; -.
DR   MaxQB; Q61036; -.
DR   PaxDb; Q61036; -.
DR   PRIDE; Q61036; -.
DR   ProteomicsDB; 287772; -. [Q61036-1]
DR   ProteomicsDB; 287773; -. [Q61036-2]
DR   Antibodypedia; 29512; 532 antibodies from 37 providers.
DR   DNASU; 18481; -.
DR   Ensembl; ENSMUST00000033640; ENSMUSP00000033640; ENSMUSG00000031284. [Q61036-1]
DR   Ensembl; ENSMUST00000112863; ENSMUSP00000108484; ENSMUSG00000031284. [Q61036-1]
DR   Ensembl; ENSMUST00000112864; ENSMUSP00000108485; ENSMUSG00000031284. [Q61036-2]
DR   Ensembl; ENSMUST00000112865; ENSMUSP00000108486; ENSMUSG00000031284. [Q61036-2]
DR   Ensembl; ENSMUST00000112868; ENSMUSP00000108489; ENSMUSG00000031284. [Q61036-2]
DR   Ensembl; ENSMUST00000172330; ENSMUSP00000126562; ENSMUSG00000031284. [Q61036-2]
DR   GeneID; 18481; -.
DR   KEGG; mmu:18481; -.
DR   UCSC; uc009umg.2; mouse. [Q61036-1]
DR   UCSC; uc009umh.2; mouse. [Q61036-2]
DR   CTD; 5063; -.
DR   MGI; MGI:1339656; Pak3.
DR   VEuPathDB; HostDB:ENSMUSG00000031284; -.
DR   eggNOG; KOG0578; Eukaryota.
DR   GeneTree; ENSGT00950000182988; -.
DR   HOGENOM; CLU_000288_26_6_1; -.
DR   InParanoid; Q61036; -.
DR   OMA; WYDASAT; -.
DR   PhylomeDB; Q61036; -.
DR   TreeFam; TF105351; -.
DR   BRENDA; 2.7.11.1; 3474.
DR   Reactome; R-MMU-202433; Generation of second messenger molecules.
DR   Reactome; R-MMU-389359; CD28 dependent Vav1 pathway.
DR   Reactome; R-MMU-3928664; Ephrin signaling.
DR   Reactome; R-MMU-399954; Sema3A PAK dependent Axon repulsion.
DR   Reactome; R-MMU-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-MMU-5621575; CD209 (DC-SIGN) signaling.
DR   Reactome; R-MMU-5627123; RHO GTPases activate PAKs.
DR   Reactome; R-MMU-5687128; MAPK6/MAPK4 signaling.
DR   Reactome; R-MMU-9013148; CDC42 GTPase cycle.
DR   Reactome; R-MMU-9013149; RAC1 GTPase cycle.
DR   Reactome; R-MMU-9013409; RHOJ GTPase cycle.
DR   Reactome; R-MMU-9013420; RHOU GTPase cycle.
DR   BioGRID-ORCS; 18481; 0 hits in 75 CRISPR screens.
DR   ChiTaRS; Pak3; mouse.
DR   EvolutionaryTrace; Q61036; -.
DR   PRO; PR:Q61036; -.
DR   Proteomes; UP000000589; Chromosome X.
DR   RNAct; Q61036; protein.
DR   Bgee; ENSMUSG00000031284; Expressed in ventromedial nucleus of hypothalamus and 186 other tissues.
DR   ExpressionAtlas; Q61036; baseline and differential.
DR   Genevisible; Q61036; MM.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005768; C:endosome; ISO:MGI.
DR   GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO.
DR   GO; GO:0014069; C:postsynaptic density; IDA:SynGO.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0051020; F:GTPase binding; ISO:MGI.
DR   GO; GO:0004708; F:MAP kinase kinase activity; ISS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; IDA:MGI.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; ISO:MGI.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0031267; F:small GTPase binding; IPI:BHF-UCL.
DR   GO; GO:0007409; P:axonogenesis; IMP:UniProtKB.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IDA:MGI.
DR   GO; GO:0016358; P:dendrite development; IMP:UniProtKB.
DR   GO; GO:0060996; P:dendritic spine development; IGI:MGI.
DR   GO; GO:0060997; P:dendritic spine morphogenesis; IMP:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0061003; P:positive regulation of dendritic spine morphogenesis; ISO:MGI.
DR   GO; GO:2000573; P:positive regulation of DNA biosynthetic process; ISO:MGI.
DR   GO; GO:0010763; P:positive regulation of fibroblast migration; ISO:MGI.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; ISO:MGI.
DR   GO; GO:0006468; P:protein phosphorylation; ISO:MGI.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; ISO:MGI.
DR   GO; GO:0030833; P:regulation of actin filament polymerization; ISS:UniProtKB.
DR   GO; GO:0050770; P:regulation of axonogenesis; IBA:GO_Central.
DR   GO; GO:0043408; P:regulation of MAPK cascade; IBA:GO_Central.
DR   GO; GO:0010975; P:regulation of neuron projection development; ISO:MGI.
DR   CDD; cd01093; CRIB_PAK_like; 1.
DR   CDD; cd06656; STKc_PAK3; 1.
DR   Gene3D; 3.90.810.10; -; 1.
DR   IDEAL; IID50053; -.
DR   InterPro; IPR000095; CRIB_dom.
DR   InterPro; IPR036936; CRIB_dom_sf.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR033923; PAK_BD.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR035063; STK_PAK3.
DR   Pfam; PF00786; PBD; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00285; PBD; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50108; CRIB; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Allosteric enzyme; Alternative splicing; ATP-binding;
KW   Cytoplasm; Developmental protein; Kinase; Magnesium; Metal-binding;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; SH3-binding; Transferase; Ubl conjugation.
FT   CHAIN           1..559
FT                   /note="Serine/threonine-protein kinase PAK 3"
FT                   /id="PRO_0000086470"
FT   DOMAIN          70..83
FT                   /note="CRIB"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00057"
FT   DOMAIN          283..534
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..70
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          65..150
FT                   /note="Autoregulatory region"
FT                   /evidence="ECO:0000250"
FT   REGION          65..123
FT                   /note="GTPase-binding"
FT                   /evidence="ECO:0000250"
FT   REGION          84..282
FT                   /note="Linker"
FT   REGION          171..215
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        18..32
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        56..70
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        184..201
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        402
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         289..297
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         312
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         2
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62829"
FT   MOD_RES         4
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62829"
FT   MOD_RES         50
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:Q62829"
FT   MOD_RES         154
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:Q62829"
FT   MOD_RES         186
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         436
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:Q62829"
FT   VAR_SEQ         93..107
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10352232,
FT                   ECO:0000303|PubMed:12464619, ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:7559398"
FT                   /id="VSP_010243"
FT   MUTAGEN         67
FT                   /note="R->C: Decreases interaction of PAK3 with CDC42 but
FT                   increases interaction with RAC1."
FT                   /evidence="ECO:0000269|PubMed:17537723"
FT   MUTAGEN         78
FT                   /note="H->L: When expressed in hippocampal neurons,
FT                   strongly decreases the number of dendritic spines; when
FT                   associated with L-81 and R-312."
FT                   /evidence="ECO:0000269|PubMed:15800193"
FT   MUTAGEN         81
FT                   /note="H->L: When expressed in hippocampal neurons,
FT                   strongly decreases the number of dendritic spines; when
FT                   associated with L-78 and R-312."
FT                   /evidence="ECO:0000269|PubMed:15800193"
FT   MUTAGEN         312
FT                   /note="K->A: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:15574732"
FT   MUTAGEN         312
FT                   /note="K->R: When expressed in hippocampal neurons,
FT                   decreases the number of dendritic spines. Strong decrease
FT                   in the number of dendritic spines; when associated with L-
FT                   78 and L-81."
FT                   /evidence="ECO:0000269|PubMed:15800193"
FT   MUTAGEN         436
FT                   /note="T->E: When expressed in hippocampal neurons,
FT                   increases the density of both spines and dendritic
FT                   protrusions."
FT                   /evidence="ECO:0000269|PubMed:15800193"
FT   CONFLICT        176
FT                   /note="A -> G (in Ref. 1; AAC52354)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        286
FT                   /note="F -> L (in Ref. 1 and 3)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        376
FT                   /note="E -> V (in Ref. 1; AAC52354)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        508
FT                   /note="R -> H (in Ref. 1; AAC52354)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        540
FT                   /note="L -> M (in Ref. 3; AAC31969)"
FT                   /evidence="ECO:0000305"
FT   HELIX           115..118
FT                   /evidence="ECO:0007829|PDB:1EES"
SQ   SEQUENCE   559 AA;  62398 MW;  9AD07B0328F0B08C CRC64;
     MSDSLDNEEK PPAPPLRMNS NNRDSSALNH SSKPLPMAPE EKNKKARLRS IFPGGGDKTN
     KKKEKERPEI SLPSDFEHTI HVGFDAVTGE FTPDLYGSQM CPGKLPEGIP EQWARLLQTS
     NITKLEQKKN PQAVLDVLKF YDSKETVNNQ KYMSFTSGDK SAHGYIAAHQ SNTKTASEPP
     LAPPVSEEED EEEEEEEDDN EPPPVIAPRP EHTKSIYTRS VVESIASPAA PNKEDIPPSA
     ENANSTTLYR NTDRQRKKSK MTDEEILEKL RSIVSVGDPK KKYTRFEKIG QGASGTVYTA
     LDIATGQEVA IKQMNLQQQP KKELIINEIL VMRENKNPNI VNYLDSYLVG DELWVVMEYL
     AGGSLTDVVT ETCMDEGQIA AVCRECLQAL DFLHSNQVIH RDIKSDNILL GMDGSVKLTD
     FGFCAQITPE QSKRSTMVGT PYWMAPEVVT RKAYGPKVDI WSLGIMAIEM VEGEPPYLNE
     NPLRALYLIA TNGTPELQNP ERLSAVFRDF LNRCLEMDVD RRGSAKELLQ HPFLKLAKPL
     SSLTPLIIAA KEAIKNSSR
 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024